Alerts will be sent to your verified email
Verify EmailTLL
|
Trident Lifeline
|
Medicamen Biotech
|
Gennex Lab
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Unclassified
|
|||
|
Advertisement Spend as a % of Total Sales
|
0.14 % | n/a | n/a |
|
Financials
|
|||
|
5 yr Average ROE
|
31.52 % | 6.92 % | 8.73 % |
|
5yr average Equity Multiplier
|
2.03 | 1.44 | 1.48 |
|
5yr Average Asset Turnover Ratio
|
0.82 | 0.55 | 0.67 |
|
5yr Avg Net Profit Margin
|
16.21 % | 8.69 % | 9.84 % |
|
Price to Book
|
3.61 | 1.12 | 1.15 |
|
P/E
|
15.31 | 32.03 | 12.15 |
|
5yr Avg Cash Conversion Cycle
|
61.09 Days | 49.75 Days | 55.46 Days |
|
Inventory Days
|
72.84 Days | 84.58 Days | 55.63 Days |
|
Days Receivable
|
86.3 Days | 139.4 Days | 37.35 Days |
|
Days Payable
|
122.66 Days | 264.75 Days | 68.33 Days |
|
5yr Average Interest Coverage Ratio
|
14.53 | 7.03 | 6.72 |
|
5yr Avg ROCE
|
26.3 % | 10.34 % | 11.78 % |
|
5yr Avg Operating Profit Margin
|
16.98 % | 15.51 % | 11.73 % |
|
5 yr average Debt to Equity
|
0.47 | 0.15 | 0.18 |
|
5yr CAGR Net Profit
|
24.36 % | -11.57 % | 35.01 % |
|
5yr Average Return on Assets
|
13.79 % | 4.73 % | 5.92 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
62.85 % | 40.46 % | 23.63 % |
|
Share Pledged by Promoters
|
6.9 % | 0.0 | 17.42 % |
|
Change in Promoter Holding (3 Yrs)
|
-7.14 % | -2.75 % | 0.25 % |
|
Change in Mutual Fund Holding (3 Yrs)
|
0.0 | 0.0 | 0.0 |
|
Trident Lifeline
|
Medicamen Biotech
|
Gennex Lab
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
|
Segment Break-Up
|
Segment Break-Up
|
-
|
-
|
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|